Rapid Development of Hypertension by Sorafenib: Toxicity or Target?
Open Access
- 30 September 2009
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (19) , 5947-5949
- https://doi.org/10.1158/1078-0432.ccr-09-1717
Abstract
Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes. (Clin Cancer Res 2009;15(19):5947–9)Keywords
All Related Versions
This publication has 11 references indexed in Scilit:
- Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of TreatmentClinical Cancer Research, 2009
- Does Arterial Spin-labeling MR Imaging–measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?Radiology, 2009
- Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth InhibitionThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100Journal of Clinical Oncology, 2008
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinibAnnals of Oncology, 2008
- Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis InhibitorClinical Cancer Research, 2008
- A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and SorafenibJNCI Journal of the National Cancer Institute, 2008
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeabilityProceedings of the National Academy of Sciences, 2001
- Vascular Endothelial Growth Factor/Vascular Permeability Factor Produces Nitric Oxide–Dependent HypotensionArteriosclerosis, Thrombosis, and Vascular Biology, 1997